Alterity Therapeutics News and Activities

Alterity Therapeutics is a company listed under the stock ticker ATH (US).

View the org chart displaying its 10 main executives

Most searched biographies at Alterity Therapeutics

• David Stamler, Chief Executive Officer
• Lawrence Gozlan, Non Executive Director
• Peter Marks, Non-Executive Independent Director

Popular executive movements at Alterity Therapeutics

• Ann Cunningham has joined the company as Independent Non Executive Director  (posted on April 17 2026).
• Julian Babarczy has joined the company as Chairman of the Board  (posted on November 25 2025).
• Geoffrey Kempler, Non-Executive Chairman, has left the company  (posted on November 21 2025).

Create your alert
to follow the executive moves at Alterity Therapeutics.

Alterity Therapeutics has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).

Popular M&A news in Pharmaceuticals

• Contraline has just announced a $93 Million fundraising (posted on June 3 2026).
• Hims & Hers has acquired Eucalyptus (posted on June 2 2026).
• Apotex has filed its IPO. Its stock ticker will be TSX. (posted on June 2 2026).

Popular contacts in Pharmaceuticals

• Joaquin Duato - Chief Executive Officer and Chairman of the Board at Johnson & Johnson
• Richard Saynor - Chief Executive Officer at Sandoz
• Robert Ford - Chief Executive Officer and Chairman of the Board at Abbott

Learn more about the Pharmaceuticals industry

Press releases by Alterity Therapeutics

• Alterity Therapeutics Issues Shareholder Newsletter Highlighting Pipeline Advances and Key Upcoming Milestones - Alterity Therapeutics
• Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy - Alterity Therapeutics
• AGM 2024 Presentation - Alterity Therapeutics
• Chairman's Address 2024 Annual General Meeting - Alterity Therapeutics
• News - Alterity Therapeutics
• Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium - Alterity Therapeutics
• Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434 - Alterity Therapeutics
• Appendix 4C – Q1 FY25 Quarterly Cash Flow Report - Alterity Therapeutics
• Alterity to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024 - Alterity Therapeutics
• Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting - Alterity Therapeutics
• View more press releases Close

Social media about Alterity Therapeutics

• Alterity Therapeutics on Wikipedia, Google News & Yahoo Finance
• Alterity Therapeutics on LinkedIn, X (Twitter) & YouTube